<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-02T11:24:33+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【招募患者】胶质母细胞瘤完成同步放化疗后淋巴细胞减少的患者中评价TJ107疗效和安全性的随机、单盲、安慰剂对照Ⅱ期临床研究</title>
    <updated>2020-12-02T09:22:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/e1t3z3uyEjkTABFbKsujlg</id>
    <link href="https://mp.weixin.qq.com/s/e1t3z3uyEjkTABFbKsujlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】盐酸杰克替尼片治疗中、重度特应性皮炎患者的多中心、随机、双盲、安慰剂平行对照II期临床研究</title>
    <updated>2020-12-02T09:22:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/1yydIdSIFwRNCKCIys__Vw</id>
    <link href="https://mp.weixin.qq.com/s/1yydIdSIFwRNCKCIys__Vw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达CTLA-4招募6】评估IBI310联合信迪利单抗晚期宫颈癌的有效性和安全性的随机、双盲、对照的平行队列Ⅱ期临床研究</title>
    <updated>2020-12-01T15:25:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/k7sNTCuyGy47gyzQDurBUQ</id>
    <link href="https://mp.weixin.qq.com/s/k7sNTCuyGy47gyzQDurBUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项评估巴瑞替尼在重度或极重度斑秃成人患者中的有效性和安全性的多中心、随机、双盲、安慰剂对照、3期研究</title>
    <updated>2020-12-01T15:25:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/QkDFau_xKRtMAS5gECCPmw</id>
    <link href="https://mp.weixin.qq.com/s/QkDFau_xKRtMAS5gECCPmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【罗氏PD-L1招募患者27】阿替利珠单抗和曲妥珠单抗联合卡培他滨和奥沙利铂用于HER2阳性局部进展期可切除胃癌的II期临床研究</title>
    <updated>2020-11-30T07:53:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/I9l0X3_n7_qXhliKTc1yGg</id>
    <link href="https://mp.weixin.qq.com/s/I9l0X3_n7_qXhliKTc1yGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估Hemay808不同浓度给药方案用于轻中度特应性皮炎患者的多中心、随机、盲法、赋形剂平行对照的Ⅱ期临床研究</title>
    <updated>2020-11-30T07:53:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/LpjFI1U3AmOf4zDW6LjU1A</id>
    <link href="https://mp.weixin.qq.com/s/LpjFI1U3AmOf4zDW6LjU1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价C019199片在实体瘤中的安全性、耐受性、PK和抗肿瘤活性的多中心、开放、剂量递增的I期临床研究</title>
    <updated>2020-11-29T09:12:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/VAU_SXuw1Twmo4tN_3vKHg</id>
    <link href="https://mp.weixin.qq.com/s/VAU_SXuw1Twmo4tN_3vKHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项在成人斑秃患者中评价SHR0302片的有效性和安全性的随机、双盲和安慰剂对照Ⅱ期研究</title>
    <updated>2020-11-29T09:12:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/ALvbRPYGghdoickKUKSj_Q</id>
    <link href="https://mp.weixin.qq.com/s/ALvbRPYGghdoickKUKSj_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者4】IBI318联合常规TACE围手术期治疗潜在可切除的肝细胞癌安全性和有效性的Ib期研究</title>
    <updated>2020-11-28T18:04:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-28:/s/j7n01XSGXhuASw_uh6lDbQ</id>
    <link href="https://mp.weixin.qq.com/s/j7n01XSGXhuASw_uh6lDbQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者3】IBI318治疗晚期皮肤鳞状细胞癌有效性和安全性的单臂、开放、多中心、Ib/II期研究</title>
    <updated>2020-11-27T10:48:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/q8NeH-4hRR4nMdvjmRxf8w</id>
    <link href="https://mp.weixin.qq.com/s/q8NeH-4hRR4nMdvjmRxf8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国产新冠疫苗向药监局提出上市申请</title>
    <updated>2020-11-26T07:17:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/Cqy7Npnkf4Eg4P3AIX3QWg</id>
    <link href="https://mp.weixin.qq.com/s/Cqy7Npnkf4Eg4P3AIX3QWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者2】评估IBI318治疗复发难治结外NK/T细胞淋巴瘤（鼻型）疗效安全Ib/II期临床研究</title>
    <updated>2020-11-26T07:17:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/k_2xMZZdciuy9sC6dnV95Q</id>
    <link href="https://mp.weixin.qq.com/s/k_2xMZZdciuy9sC6dnV95Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在非小细胞肺癌评估 JNJ-73841937单药治疗或与JNJ-61186372联合治疗安全性和PK I/Ib期研究</title>
    <updated>2020-11-25T08:02:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/7rLzY0mw7-rcKN3ZybOvoA</id>
    <link href="https://mp.weixin.qq.com/s/7rLzY0mw7-rcKN3ZybOvoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价BI655130与安慰剂相比在具有泛发性脓疱性银屑病病史的患者中预防GPP发作的有效性和安全性的IIb期研究</title>
    <updated>2020-11-25T08:02:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/qseNj-uz3MOeTY1zdqYQQA</id>
    <link href="https://mp.weixin.qq.com/s/qseNj-uz3MOeTY1zdqYQQA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】SHR3680联合多西他赛治疗前列腺癌的II期临床研究</title>
    <updated>2020-11-24T08:30:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/Gnd1Cyy2dbRv0Y7Q8pfAuw</id>
    <link href="https://mp.weixin.qq.com/s/Gnd1Cyy2dbRv0Y7Q8pfAuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价Tildrakizumab治疗中度至重度斑块状银屑病的疗效及安全性的随机、双盲、安慰剂对照、多中心临床试验</title>
    <updated>2020-11-24T08:30:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/c3hWyYJDoAMCFN1917eAcw</id>
    <link href="https://mp.weixin.qq.com/s/c3hWyYJDoAMCFN1917eAcw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】AB-106 治疗携带NTRK 融合基因的局部进展或全身转移的实体瘤受试者的一项Ⅱ期、多中心、开放、篮式研究</title>
    <updated>2020-11-23T08:09:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/L9o59_RokkzPCnHQGpTv1A</id>
    <link href="https://mp.weixin.qq.com/s/L9o59_RokkzPCnHQGpTv1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>